Redemptive benefit of atorvastatin in the risk factors of coronary artery disease

Jayaraman Gowri , Arumugam Vijaya Anand , Shanmugam Achiraman , Govindha Raj Archunan , Subramaniyam Kalavathy , Palanisamy Sampath Kumar , Kalaiyarasan Vijaya Kumar Int J Cur Biomed Phar Res. (2011) Redemptive benefit of atorvastatin in the risk factors of coronary artery disease. [Journal (Paginated)]

Full text available as:

PDF (Redemptive benefit of atorvastatin in the risk factors of coronary artery disease) - Published Version
Available under License Creative Commons Attribution No Derivatives.



Cardiovascular disease, in particular coronary artery disease (CAD), is the principal cause of mortality in developed countries. The classical acute phase protein, C-reactive protein (CRP) is an exquisitely sensitive systemic marker of disease with broad clinical utility for monitoring and differential diagnosis. In recent years, acute phase reactants have been shown to predict future cardiovascular events in individuals with and without established CAD. Atorvastatin, a 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor, substantially reduce cardiovascular morbidity and mortality, and recently their anti-inflammatory properties have been investigated. The present study was therefore designed to determine the effects of atorvastatin on CRP in patients with CAD. Ninety two patients with or without or at the risk of CAD were recruited for the study, of which 35 belongs to control (untreated) and 57 were test group, in which, 30 of them received daily with 20 mg/day of atorvastatin and the remaining 27 were untreated. The patients were followed for over a period of 6 weeks. For entire study population, CRP along with lipid profile, SGOT, SGPT, urea and creatinine were measured 1st day and at the end of 6th week of the treatment. For patients with or at risk of CAD, the reduced rate of progression of atherosclerosis associated with intensive atorvastatin treatment, as compared with control is significantly related to greater reduction in the levels of both atherogenic lipoproteins and CRP. This may be important with respect to the early benefits of atorvastatin therapy.

Item Type:Journal (Paginated)
Keywords:Inflammation, C-reactive protein, Coronary artery disease, Statins.
ID Code:7326
Deposited By: CurrentSciDirect Publications, International Journal of Current Biomedical and Pharmaceutical Research (IJCBPR)
Deposited On:02 May 2011 15:51
Last Modified:02 May 2011 15:51

References in Article

Select the SEEK icon to attempt to find the referenced article. If it does not appear to be in cogprints you will be forwarded to the paracite service. Poorly formated references will probably not work.

Murray CJL, Lopez AD. The Global Burden of Disease: A Comprehensive Assessment of Mortality and Disability From Disease. Injuries and Risk Factors in 1990 and Projected to 2020. Cambridge, Mass: Harvard University Press, 1996.

2. Ross R. Atherosclerosis is an inflammatory disease. Am Heart J. 1999; 138:S419–20.

3. Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation. 2002; 105:1135–43.

4. Libby P, Ridker PM. Inflammation and atherosclerosis: role of C-reactive protein in risk assessment. Am J Med. 2004; 116(Suppl6A):9S–16S.

5. Danesh J, Collins R, Appleby P, Peto R. Association of fibrinogen, C-reactive protein, albumin, or leukocyte count with coronary heart disease: meta-analyses of prospective studies. JAMA. 1998; 279:1477–1482.

6. Koenig W, Sund M, Frohlich M, Fischer HG, Lowel H. C-Reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: results from the MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) Augsburg Cohort Study, 1984 to 1992. Circulation. 1999; 99:237–242.

7. Ridker PM, Hennekens CH, Buring JE, Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med. 2000; 342:836–843.

8. Ridker PM, Rifai N, Pfeffer MA, Sacks FM, Moye LA, Goldman S, Flaker GC, Braunwald E. For the Cholesterol and Recurrent Events (CARE) Investigators. Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Circulation. 1998; 98:839– 44.

9. Black S, Kushner I, Samols D. C-reactive protein. J Biol Chem. 2004; 279:48487–90.

10. Pepys MB, Hirschfield GM. C-reactive protein and atherothrombosis. Ital Heart J. 2001; 2:196–9.

11. Sesso HD, Buring JE, Rifai N, Blake GJ, Michael GJ Ridker PM, C-reactive protein and the risk of developing hypertension. JAMA. 2003; 290:2945–51.

12. Mahley RW, Bersot TP. Drug therapy for hypercholesterolemia and dyslipidemia. In. Hardman JG, Limbird LE, Gilman AG. eds. Goodman & Gilman”s The Pharmacological Basis of Therapeutics. 10th ed. New York: McGraw Hill, 2001; 71:1002.

13. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomized placebo-controled trial. Lancet. 2002; 360:7–22.

14. Furberg CD. Natural statins and stroke risk. Circulation. 1999; 99:185–188.

15. Scandinavian Simvastatin Survival Study (4S) Group. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian simvastatin survival study (4S). Lancet. 1994; 344:1383–1389.

16. Downs JR, Clearfield M, Weis S, Whitney E, Sharpio DR. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/T ex CAPS. Air Force/Texas Coronary Atherosclerosis prevention Study. JAMA. 1998; 279:1615–1622.

17. Sacks FM, Pfeffr MA, Moye LA Rouleau JL, Rutherford JD.The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial Investigators. N Engl J Med. 1996; 335:1001–9.

18. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR.For the West of Scotland Coronary Prevention Study Group. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med. 1995; 333:1301–1307.

19. Bonetti PO, Lerman LO, Napoli C, Lerman A.. Statin effects beyond lipid lowering-are they clinically relevant? Eur Heart J. 2003; 24:225–48.

20. Wright RS, Murphy JG, Bybee KA, Kopecky SL, LaBlanche JM. Statin lipid-lowering therapy for acute myocardial infarction and unstable angina: efficacy and mechanism of benefit. Mayo Clin Proc. 2002; 77:1085–92.

21. Fenton JW II, Shen GX. Statins as cellular antithrombotics. Haemostasis. 1998; 29:166–169.

22. Rosenson RS, Tangney CC. Antiatherothrombotic properties of statins: implications for cardiovascular event reduction [Review]. JAMA. 1998; 279(20):1643–50.

23. Berkenboom G. Unstable atheroslerotic plaque: pathophysiology and therapeutic guidelinpes. Acta Cardiol. 1998; 53:235–241.

24. Weissberg PL. Atherosclerosis involves more than just lipids: plaque dynamics. Eur Heart J. 1999; 1 (suppl):T13–T18.

25. Yu H, Rifai N. High-sensitivity C-reactive protein and atherosclerosis from theory to therapy. Clin Biochem. 2000; 33:601–10.

26. Ferreiros ER, Boissonnet CP, Pizarro R, García Merletti PF, Corrado G, Cagide A, Bazzino OO. Independent prognostic value of elevated C-reactive protein in unstable angina. Circulation. 1999; 100:1958–63.

27. Ridker PM, Rifai N, Pfeffer MA, Sacks F, Braunwald E. Long term effects of pravastatin on plasma concentration of C-reactive protein. The Cholesterol and Recurrent Events (CARE) Investigators. Circulation. 1999; 100:230–5.

28. Albert MA, Danielson E, Rifai N, Ridker PM, The PRINCE Investigators. Effect of statin therapy on C-reactive protein levels: the Pravastatin Inflammation/CRP Evaluation (PRINCE): a randomized trial and cohort study. JAMA. 2001; 286:64–70.

29. Taylor AJ, Kent SM, Flaherty PJ, Coyle LC, Markwood TT, Vernalis MN. ARBITER: Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol: a randomized trial comparing the effects of atorvastatin and pravastin on carotid intima medical thickness. Circulation. 2002; 106:2055–60.

30. Nissen SE, Tuzcu EM, Schoenhagen P, Brown BG, Ganz P.AN; REVERSAL Investigators. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. J Am Med Assoc. 2004; 291:1071–80.

31. Wiklund O, Mattsson-Hulten L, Hurt-Camejo E, Oscarsson J. Effects of simvastatin and atorvastin on inflammation markers in plasma. J Intern Med. 2002; 251:338–47.

32. Ridker PM, Cannon CP, Morrow D, Rifai N, Rose LM. Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 (PROVE IT-TIMI 22) Investigators 2005. C-reactive protein levels and outcomes after statin therapy. New Engl J Med. 2005; 352:20–8.

33. Tsunekawa T, Hayashi T, Kano H, Sumi H, Matsui H, Thakur NK, Egashira K, Iguchi A. Cerivastatin, a hydroxy methyl coenzyme A inhibitor, improves endothelial function in elderly diabetic patients within 3 days. Circulation. 2001; 104:376–9.


Repository Staff Only: item control page